drugset
drugset / Trial / NCT01349296

BIBF 1120 and RAD001 in Solid Tumors - Phase I

NCT01349296 ↗

Phase 1 Completed 18 enrolled University of Cologne Boehringer Ingelheim · collab
NaSingle-groupOpen-labelTreatment

Summary

BIBF1120 and RAD001 in solid tumors

Timeline

Start
2012-07
Primary completion
2014-10
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 5 mg —
Subject Everolimus Small molecule 10 mg —
Subject Nintedanib Small molecule 150 mg —
Subject Nintedanib Small molecule 200 mg —

Indications

cancer